Hinge Health Inc. (NYSE:HNGE - Get Free Report)'s share price reached a new 52-week high during mid-day trading on Monday . The stock traded as high as $45.98 and last traded at $45.28, with a volume of 467962 shares traded. The stock had previously closed at $42.07.
Analyst Upgrades and Downgrades
A number of brokerages recently commented on HNGE. Morgan Stanley started coverage on shares of Hinge Health in a research note on Monday, June 16th. They set an "overweight" rating and a $46.00 target price for the company. Royal Bank Of Canada initiated coverage on Hinge Health in a report on Monday, June 16th. They issued an "outperform" rating and a $45.00 price objective on the stock. Canaccord Genuity Group initiated coverage on Hinge Health in a research note on Monday, June 16th. They set a "buy" rating and a $52.00 target price for the company. Needham & Company LLC assumed coverage on shares of Hinge Health in a research note on Monday, June 16th. They issued a "buy" rating and a $47.00 price target on the stock. Finally, Wall Street Zen raised shares of Hinge Health to a "hold" rating in a report on Monday, June 2nd. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $46.00.
Get Our Latest Stock Report on Hinge Health
Hinge Health Stock Up 7.3%
Hinge Health Company Profile
(
Get Free Report)
Our vision is to build a new health system that transforms outcomes, experience and costs by using technology to scale and automate the delivery of care. Hinge Health leverages software, including AI, to largely automate care for joint and muscle health, delivering an outstanding member experience, improved member outcomes, and cost reductions for our clients.
Featured Stories
Before you consider Hinge Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Hinge Health wasn't on the list.
While Hinge Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
